Introduction
Chronic myelogenous leukemia (CML) has an incidence of 1-2 per 100 000 adults and accounts for 15% of leukemias. 1 The most commonly used treatment for all phases of the disease (CP (chronic), AP (accelerated) and BP (blast)), is imatinib (Glivec; Gleevec, Novartis, Basel, Switzerland). 2 Despite inducing hematologic (HR) and cytogenetic (CyR) responses, imatinib is associated with a significant frequency of resistance and intolerance. [3] [4] [5] Dasatinib (SPRYCEL; Bristol-Myers Squibb, New York, NY, USA), a potent inhibitor of BCR-ABL (325-fold greater potency than imatinib in vitro) and SRC family kinases, 6, 7 is approved for patients with CP, AP, or myeloid or lymphoid BP-CML who are resistant or intolerant to prior therapy including imatinib.
Data on the initial 186 patients (minimum follow-up of 8 months) of a multicenter, multinational phase II trial evaluating the efficacy and safety of dasatinib in CP-CML resistant or intolerant to imatinib therapy (known as START-C) have been previously reported. 8 Results are now available for the entire patient cohort (387 patients) with a longer term follow-up (median length of follow-up, 15.2 months; treatment duration, o1-18.4 months)Fmore than doubling the size of this trial and enabling a more definitive evaluation of dasatinib therapy in the treatment of patients with imatinib-resistant or -intolerant CP-CML. Our earlier report demonstrated that dasatinib induced notable rates of HR and CyR in this population (complete HR (CHR), 90% and major CyR response (MCyR), 52%). MCyRs were maintained for 96% of patients with imatinib-resistant disease and 100% of patients with imatinib-intolerant CP-CML throughout the available follow-up. Response rates were similar for patients with or without BCR-ABL mutations conferring imatinib resistance.
This longer term follow-up on the full cohort of patients provides a robust analysis of the response to continued treatment with dasatinib. Our results, with treatment duration extending to 18 months, show that dasatinib is associated with a high rate of response (CHR and MCyR) in patients with imatinibresistant or -intolerant CP-CML.
Study design and patient eligibility
This open-label, single-arm, international phase II study was conducted in accordance with the Declaration of Helsinki, and was consistent with International Conference on Harmonization Good Clinical Practice (ICH GCP) and applicable regulatory requirements. Written informed consent was obtained from all patients.
Entry criteria have been described previously. 8 Briefly, patients aged at least 18 years were eligible if they had imatinib-resistant or -intolerant CP-CML. Exclusion criteria included imatinib therapy within 7 days of initiation, an Eastern Cooperative Oncology Group (ECOG) performance status greater than 1, uncontrolled or significant cardiovascular disease, or a history of a significant bleeding disorder unrelated to CML.
Treatment with dasatinib
Dasatinib was administered orally at 70 mg twice daily (b.i.d.). Escalation to 90 mg dasatinib b.i.d. was permitted for patients who had disease progression, no CHR after 8 weeks or no MCyR after 12 weeks. For patients with cytopenia of grade 3 or more, certain non-hematologic toxicities of grade 2 or more (for example, nausea/vomiting and diarrhea), or bleeding events, dose interruption or reduction to 50 or 40 mg b.i.d. was allowed. Treatment was subsequently reinitiated at the previous dose or at a reduced dose level, or discontinued altogether, depending on the severity and recurrence of the adverse event. Dasatinib treatment continued until withdrawal from the study, intolerable toxicity or progression of CML despite dose escalation. All patients continued dasatinib on a b.i.d. regimen throughout the reported follow-up, except for three patients who were switched by the investigator to once-daily treatment (2-100 mg q.d. and 1-140 mg q.d.).
Patient evaluations
Definitions of response have been defined previously. 8 HRs were assessed by complete blood counts. CyRs were monitored by bone marrow aspirates and/or biopsies (every 12 weeks), and were based on the proportion of Ph þ metaphases among mitotic cells in bone marrow samples.
A conservative definition of disease progression was used in this study, where any one of the following meant that a patient had progressed: development of AP-CML, development of BP-CML, loss of MCyR, loss of CHR or an increasing WBC count (defined as a doubling of the count from lowest value to 420 000/mm 3 or an increase by 450 000/mm 3 on two occasions at least 2 weeks apart).
Clinical assessments included physical examination (weekly for 4 weeks then monthly) and laboratory tests on blood and urine samples throughout the trial.
Subjects had to be on study for 414 days to be assessed for progression/relapse.
Statistical analysis
Analysis of efficacy parameters was performed for all patients receiving at least one dose of dasatinib. For the CHR and MCyR rates, a two-sided 95% exact confidence interval (CI) was calculated using the Clopper-Pearson method. 9 Durations of CHR and MCyR were estimated using Kaplan-Meier productlimit methodology and were measured from the first day these criteria were met until the date treatment was discontinued due to progressive disease or death. Patients who discontinued for other reasons were censored on the date of their last cytogenetic assessment. For median duration of CHR and MCyR, two-sided 95% CIs were computed using the method of Brookmeyer and Crowley. 10 Progression-free survival and overall survival were estimated using the Kaplan-Meier method.
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0.
Results

Patient demographics and disease characteristics
Between 4 February and 10 August 2005, 387 patients were recruited from 75 centers worldwide. Patient demographics and baseline disease characteristics were consistent with other reports of patients with imatinib-resistant or -intolerant CP-CML (Table 1) .
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Most imatinib-resistant patients had received high-dose imatinib (4600 mg/day) prior to study entry (72%), and 53% of all patients had been treated with imatinib for more than 3 years, indicating a significant population of late CP patients. During prior imatinib therapy, 82% of patients had experienced a CHR and 37% an MCyR (complete cytogenetic response (CCyR), 19%).
Efficacy
Hematologic and cytogenetic responses. Dasatinib therapy resulted in a marked CHR rate for patients with CP-CML. A CHR was maintained or achieved in 351/387 patients (91%) (95% CI: 87.4-93.4%) ( Table 2 ). Rates of CHR were 90 and 94% for imatinib-resistant and -intolerant subgroups, respectively. Of the 154 patients entering the study with a CHR at baseline, CHRs were maintained in 149 patients (97%; imatinib resistant: 100/103 and imatinib intolerant: 49/51). A CHR was achieved in 87% of patients (202/233) with no CHR at baseline (imatinib resistant: 158/185 and imatinib intolerant: 44/48). Time to CHR was short, with the majority of patients achieving their response by the time of first assessment (15 days; 95% CI: [15] [16] [17] . Moreover, responses were durable and the median duration of response was not reached at 18 months ( Figure 1a ). In all, 24/ 258 (9%) imatinib-resistant patients and 3/93 (3%) imatinibintolerant patients achieving a CHR with dasatinib subsequently experienced disease progression.
Dasatinib also induced a substantial rate of CyRs in this setting (Table 2 ). MCyRs and CCyRs were maintained or achieved in 230 (59%; 95% CI: 54.4-64.4%) and 189 patients (49%), respectively. Of the 288 imatinib-resistant patients, 151 (52%) achieved MCyRs, of whom 115 (40%) attained CCyRs. Of the 99 patients with imatinib-intolerant disease, 79 (80%) achieved MCyRs and 74 (75%) CCyRs. Of the 41 patients entering the study with an MCyR at baseline, 35 (85%) maintained their MCyR (imatinib resistant: 14/18 and imatinib intolerant: 21/23). Fifty-six percent of patients without an MCyR at baseline (195/346) achieved an MCyR (imatinib resistant: 137/270 and imatinib intolerant: 58/76). Further subanalyses indicated that MCyRs were consistently achieved across subgroups classified according to duration of prior imatinib therapy (p3 vs 43 years, 65 vs 55%), prior imatinib dose (p600 vs 4600 mg, 63 vs 57%); BCR-ABL mutations (mutation evident vs no mutation, 57 vs 48%) and prior HR (prior CHR vs no prior CHR, 63 vs 59%). A larger difference was observed in the rate of MCyR based on prior CyR to imatinib compared with no prior CyR to imatinib, 71 vs 42%, respectively. MCyRs induced by dasatinib were durable, with only 6/151 (4%)
Long-term follow-up of dasatinib in chronic-phase CML A Hochhaus et al imatinib-resistant patients and 1/79 (1%) imatinib-intolerant patients who achieved an MCyR with dasatinib subsequently experiencing disease progression (Figure 1b) . Of these seven patients, four had achieved a CCyR and three a partial cytogenetic response (PCyR) before progression. Of the four patients who progressed following a CCyR, three had developed new BCR-ABL mutations (V299L, T315I and E459K). Time to MCyR was short, with the majority of patients achieving an MCyR by the time of their first assessment (85 days; 95% CI: 85-87). Table 2 Best hematologic and cytogenetic responses to dasatinib 
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Progression-free survival. Despite a conservative definition of progression-free survival and a median follow-up of 15.2 months (range: o1-18.4), the estimated progression-free survival was 90% (Figure 2a) . Of the 40 patients (10%) experiencing disease progression, 37 had imatinib-resistant disease.
Overall survival. The estimated overall survival rate was 96% ( Figure 2b) . All of the patients (4%, 14/387) who had died at the time of analysis were imatinib resistant (one patient died after achieving a CCyR). Reasons for death assigned by study investigators were CML disease (n ¼ 6), cardiovascular disease (n ¼ 2), infection (n ¼ 2), central nervous system bleed (n ¼ 1) and other causes (n ¼ 3).
Analysis of efficacy by baseline BCR-ABL mutational status. Both HR and CyR were observed broadly across BCR-ABL genotypes (Table 3) . At baseline, ABL kinase domain analysis identified mutations associated with imatinib resistance in 139/345 (40%) of tested patients. Among these 139 patients, 43 distinct imatinib-resistant mutations were detected. Mutations associated with moderate to very high resistance to imatinib (Xfivefold increase in cellular IC 50 compared with unmutated BCR-ABL) were found in 77/345 (22%) patients. As expected, dasatinib had no activity in all three patients with the T315I mutation.
Safety and tolerability
Overall, dasatinib had acceptable tolerability and a manageable safety profile. Incidences of the most common treatment-related adverse events were comparable between imatinib-resistant and -intolerant cohorts (data not shown).
The most frequent non-hematologic adverse events, reported by 420% of patients, were diarrhea, headache, fatigue, dyspnea, pleural effusion, rash and nausea (Table 4) . Peripheral edema related to dasatinib was reported by 18% of patients, and was only classified as grade 1 or 2. The most frequent grade 3/4 non-hematologic events were pleural effusion (6.2%), dyspnea (5.2%) and diarrhea (2.8%). No grade 4 (life-threatening) pleural effusions were reported. Other cases of fluid retention were rare. In all, 22 patients (6%) experienced some degree of congestive heart failure and 14 cases (4%) were classified as grades 3/4. Arrhythmias occurred in 16 patients (4%; grades 3/4, five patients (1%)). Grade 3/4 thrombocytopenia and neutropenia occurred in 48 and 49% of patients, respectively.
Dasatinib treatment
Modifications to the dasatinib dose were common during this trial. Dose reductions occurred in 283/387 (73%) of patients, and the rate was similar in imatinib-resistant (73%) andintolerant (75%) subpopulations. The main reasons for the first dose reduction were hematologic toxicity (n ¼ 152, 39%), nonhematologic toxicity (n ¼ 111, 29%) and dosing error (n ¼ 13, 3%). For the overall population, 87% of patients required dose Long-term follow-up of dasatinib in chronic-phase CML A Hochhaus et al interruptions, and the most common reasons for the first treatment interruption were again hematologic (44%) or nonhematologic (35%) toxicity. The median length of first interruption for hematologic toxicity was 18 days. Dasatinib dose was escalated for 69/387 (18%) patients, with the main reason for first dose escalation being lack of MCyR at 12 weeks (5%).
At a median follow-up of 15.2 months, the majority of patients were still receiving dasatinib therapy (n ¼ 268; 69%).
Reasons for treatment discontinuation, as assigned by study investigators, were disease progression (n ¼ 29, 7%), drug toxicity (n ¼ 49, 13%; hematologic, n ¼ 18 and non-hematologic, n ¼ 31), non-treatment-related adverse events (n ¼ 9, 2%), death (n ¼ 4, 1%), elective stem cell transplantation (n ¼ 8, 2%) and other reasons (n ¼ 20, 5%).
The median duration of dasatinib therapy for all treated patients was 13.8 months (range: o1-18.4 months). The 
Table 3
Response by baseline BCR-ABL mutation Abbreviations: CHR, complete hematologic response; MCyR, major cytogenetic response.
Long-term follow-up of dasatinib in chronic-phase CML A Hochhaus et al majority of patients received treatment for more than 6 months: 84% (total), 83% (imatinib resistant) and 87% (imatinib intolerant). The median daily dose of dasatinib was 101 mg (range: 11-171 mg for the total population) and was similar for imatinib-resistant (101 mg; 18-171 mg) and imatinib-intolerant (104 mg; 11-140 mg) patient subgroups.
Discussion
In this report, data from the entire cohort of 387 patients confirm the durability of CyR in patients with CP-CML receiving dasatinib therapy. Compared with the earlier report from this study (median treatment duration 8.3 months), 8 the HR rate was similar (CHR, from 90 to 91%) and the CyR rate was substantially improved (MCyR, from 52 to 59% and CCyR, from 39 to 49%) with longer term follow-up (median treatment duration 13.8 months).
Rates of response were consistently high across the various subgroups examined, indicating that dasatinib provides broadranging treatment benefits. Responses in patients with BCR-ABL mutations at baseline (40% of the total population) were comparable to overall response rates, reflecting the results of separate in vitro studies of dasatinib showing a 325-fold greater potency than imatinib against unmutated BCR-ABL and inhibition of mutated BCR-ABL proteins with a high level of imatinib resistance. 5, 12 In addition to inhibiting mutated BCR-ABL proteins, dasatinib was also effective in our study in patients with imatinib-resistant disease without BCR-ABL mutations. This suggests that dasatinib may overcome other possible mechanisms of imatinib resistance, for example, BCR-ABL gene amplification, P-glycoprotein efflux pump overexpression and SRC family kinase dysregulation. [13] [14] [15] [16] [17] [18] Notably, 42% of patients who had not achieved a prior CyR of any level on prior imatinib treatment attained an MCyR with dasatinib, although the rate was higher in patients who had achieved a prior CyR with imatinib (71%).
The incidence of treatment-related adverse events was slightly higher with longer term follow-up compared with data reported from the initial cohort (n ¼ 186). 8 Increases were observed for dyspnea (all grades: 30 vs 27% and grades 3/4: 5 vs 3%) and pleural effusion (all grades: 27 vs 19% and grade 3: 6 vs 3%). No grade 4 pleural effusions were reported. Rates of cytopenias, however, were almost identical to the earlier report. In this report of the full patient cohort from the START-C study, tolerability to dasatinib treatment 70 mg b.i.d. was acceptable.
Key adverse events were manageable through protocolspecified dose reductions, dose interruptions and appropriate medical management. Growth factor support was permitted for patients who developed grade 3/4 cytopenias. In a study of 38 patients with CP-CML who developed cytopenias on dasatinib, growth factor support enabled more continuous dasatinib treatment (Quintas-Cardama et al. Blood 2006; 108: 613a (abstract 2163)). Methods of management reported for dasatinibassociated pleural effusions have included treatment interruption/reduction, diuretics and/or pulse steroid therapy. 19 There was no evidence of adverse events related to prolonged cardiac interval, which had been suggested from in vitro studies. 20 A total of 13% of patients discontinued treatment because of toxicity compared with 9% in the previous report. 8 The majority of patients recruited to this study with imatinib intolerance (defined as at least grade 3 non-hematologic toxicity or grade 4 hematologic toxicity persisting for more than 7 days, related to imatinib at any dose) were able to tolerate dasatinib. There was no significant cross-intolerance between dasatinib and imatinib noted for non-hematologic toxicities; however, patients who discontinued imatinib for hematologic toxicity frequently experienced similar toxicity with dasatinib.
The median daily dasatinib dose of 101 mg reflected a reduction in dose from a starting point of 140 mg. Data from a phase III dose-and schedule-optimization trial in CP-CML (CA180-034) has demonstrated that treatment with dasatinib (100 mg) once daily is associated with the most favorable riskbenefit ratio when compared with other dosing regimens including 70 mg b.i.d. In the 034 study, dasatinib (100 mg) once daily was associated with similar efficacy compared with other dosages but with less frequent fluid retention and cytopenia (Hochhaus et al. Haematologica 2007; 92 (Suppl 1): 128 (abstract 0359)). As a result, dasatinib (100 mg) once daily has recently been approved in the United States and Europe for patients with CP-CML who have imatinib resistance or intolerance. 20 Therapeutic options are limited for patients with CP-CML who develop resistance or intolerance to imatinib. 2 The availability of dasatinib, with its demonstrated efficacy and safety profile, provides an important treatment option for this population of patients. The data presented from the full patient cohort of this large study confirm the durability and depth of HR and CyR associated with dasatinib therapy. Further evaluation of whether these response data translate into prolonged survival is required in this clinical population.
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